MXPA05001623A - Para tratar la insuficiencia cardiaca severa y un medicamento para el mismo. - Google Patents

Para tratar la insuficiencia cardiaca severa y un medicamento para el mismo.

Info

Publication number
MXPA05001623A
MXPA05001623A MXPA05001623A MXPA05001623A MXPA05001623A MX PA05001623 A MXPA05001623 A MX PA05001623A MX PA05001623 A MXPA05001623 A MX PA05001623A MX PA05001623 A MXPA05001623 A MX PA05001623A MX PA05001623 A MXPA05001623 A MX PA05001623A
Authority
MX
Mexico
Prior art keywords
heart failure
pharmaceutically acceptable
benzazepine
acceptable salt
group
Prior art date
Application number
MXPA05001623A
Other languages
English (en)
Spanish (es)
Inventor
Yoshitaka Yamamura
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32908667&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MXPA05001623(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of MXPA05001623A publication Critical patent/MXPA05001623A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MXPA05001623A 2003-02-24 2004-02-23 Para tratar la insuficiencia cardiaca severa y un medicamento para el mismo. MXPA05001623A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44887803P 2003-02-24 2003-02-24
PCT/JP2004/002085 WO2004073716A1 (en) 2003-02-24 2004-02-23 Method for treating severe heart failure and medicament therefor

Publications (1)

Publication Number Publication Date
MXPA05001623A true MXPA05001623A (es) 2005-04-25

Family

ID=32908667

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05001623A MXPA05001623A (es) 2003-02-24 2004-02-23 Para tratar la insuficiencia cardiaca severa y un medicamento para el mismo.

Country Status (23)

Country Link
US (2) US7423032B2 (enExample)
EP (2) EP1596868B1 (enExample)
JP (2) JP4771937B2 (enExample)
KR (1) KR100706727B1 (enExample)
CN (1) CN100577171C (enExample)
AR (1) AR043259A1 (enExample)
AT (1) ATE411803T1 (enExample)
AU (2) AU2004212842B9 (enExample)
BR (1) BRPI0405657A (enExample)
CA (1) CA2493475A1 (enExample)
CY (1) CY1108583T1 (enExample)
DE (1) DE602004017283D1 (enExample)
DK (1) DK1596868T3 (enExample)
ES (1) ES2315640T3 (enExample)
MX (1) MXPA05001623A (enExample)
MY (1) MY143740A (enExample)
NO (1) NO335369B1 (enExample)
PL (2) PL218069B1 (enExample)
PT (1) PT1596868E (enExample)
RU (2) RU2346689C2 (enExample)
SI (1) SI1596868T1 (enExample)
TW (1) TWI322689B (enExample)
WO (1) WO2004073716A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7468390B2 (en) * 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
TWI322689B (en) * 2003-02-24 2010-04-01 Otsuka Pharma Co Ltd Method for treating severe heart failure and medicament therefor
DE102005003632A1 (de) 2005-01-20 2006-08-17 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Katheter für die transvaskuläre Implantation von Herzklappenprothesen
US20070213813A1 (en) 2005-12-22 2007-09-13 Symetis Sa Stent-valves for valve replacement and associated methods and systems for surgery
EP1968990B1 (en) 2005-12-27 2015-02-11 Otsuka Pharmaceutical Co., Ltd. Water-soluble benzoazepine compound and its pharmaceutical composition
JP5076327B2 (ja) * 2006-02-01 2012-11-21 味の素株式会社 分岐鎖アミノ酸の心不全適応
US7896915B2 (en) 2007-04-13 2011-03-01 Jenavalve Technology, Inc. Medical device for treating a heart valve insufficiency
UA99914C2 (ru) * 2007-05-15 2012-10-25 Оцука Фармас'Ютікел Ко., Лтд. Способ применения антагонистов вазопресина со средствами антрациклиновой химиотерапии для снижения кардиотоксичности
TWI405574B (zh) * 2007-06-21 2013-08-21 Otsuka Pharma Co Ltd 藥學固體製劑及其製造方法
BR112012021347A2 (pt) 2008-02-26 2019-09-24 Jenavalve Tecnology Inc stent para posicionamento e ancoragem de uma prótese valvular em um local de implantação no coração de um paciente
US9044318B2 (en) 2008-02-26 2015-06-02 Jenavalve Technology Gmbh Stent for the positioning and anchoring of a valvular prosthesis
US10856978B2 (en) 2010-05-20 2020-12-08 Jenavalve Technology, Inc. Catheter system
CA2799459A1 (en) 2010-05-25 2011-12-01 Jenavalve Technology Inc. Prosthetic heart valve and transcatheter delivered endoprosthesis comprising a prosthetic heart valve and a stent
JP5477413B2 (ja) * 2012-04-24 2014-04-23 味の素株式会社 分岐鎖アミノ酸の心不全適応
WO2015028209A1 (en) 2013-08-30 2015-03-05 Jenavalve Technology Gmbh Radially collapsible frame for a prosthetic valve and method for manufacturing such a frame
EP4353203B1 (en) 2015-03-20 2026-08-19 JenaValve Technology, Inc. Heart valve prosthesis delivery system
EP3632378B1 (en) 2015-05-01 2024-05-29 JenaValve Technology, Inc. Device with reduced pacemaker rate in heart valve replacement
WO2017195125A1 (en) 2016-05-13 2017-11-16 Jenavalve Technology, Inc. Heart valve prosthesis delivery system and method for delivery of heart valve prosthesis with introducer sheath and loading system
EP3573579B1 (en) 2017-01-27 2023-12-20 JenaValve Technology, Inc. Heart valve mimicry
CN110174474B (zh) * 2019-05-24 2022-02-18 石家庄四药有限公司 复方电解质注射液(ⅱ)中l-苹果酸异构体的检测方法
CN112121051B (zh) * 2020-09-30 2021-06-18 郑州大学 莫扎伐坦在制备抗消化道肿瘤药物中的应用
WO2024102411A1 (en) 2022-11-09 2024-05-16 Jenavalve Technology, Inc. Catheter system for sequential deployment of an expandable implant

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01102124A (ja) 1987-10-14 1989-04-19 Kubota Ltd コンクリート構造体支持構造
US5258510A (en) 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
KR0167349B1 (ko) 1989-10-20 1999-02-18 오스카 아끼히꼬 벤조헤테로 고리 화합물
US5753677A (en) 1989-10-20 1998-05-19 Otsuka Pharmaceutical Co., Ltd. Benzoheterocyclic compounds
EP0602209A1 (en) 1992-07-02 1994-06-22 Otsuka Pharmaceutical Co., Ltd. Oxytocin antagonist
JPH0680641A (ja) 1992-09-01 1994-03-22 Otsuka Pharmaceut Co Ltd 光学活性な５−ヒドロキシベンゾアゼピン誘導体の製造法
TW354762B (en) 1993-02-23 1999-03-21 Otsuka Pharma Co Ltd Agent for prophylaxis or treatment of cataract
JP2694319B2 (ja) 1993-12-24 1997-12-24 大塚製薬株式会社 抗潰瘍剤
JP3002766B2 (ja) 1994-12-09 2000-01-24 大塚製薬株式会社 脳浮腫治療剤
JPH10120592A (ja) 1996-10-22 1998-05-12 Otsuka Pharmaceut Co Ltd メニエール病乃至メニエール症候群治療剤
JP4210355B2 (ja) * 1997-07-03 2009-01-14 大塚製薬株式会社 固形製剤組成物
BR0017074A (pt) 2000-01-26 2002-12-03 Warner Lambert Co Combinações de inibidor de ace-antagonista de vasopressina
US20030103983A1 (en) * 2002-05-09 2003-06-05 Pressler Milton Lethan Ace inhibitor-vasopressin antagonist combinations
US20030008860A1 (en) 2002-05-09 2003-01-09 Bakker-Arkema Rebecca Guggemos Treatment of congestive heart failure
IL145684A (en) * 2000-10-04 2007-06-17 Warner Lambert Co Medications for the treatment of pulmonary hypertension
TWI322689B (en) * 2003-02-24 2010-04-01 Otsuka Pharma Co Ltd Method for treating severe heart failure and medicament therefor

Also Published As

Publication number Publication date
JP2011148806A (ja) 2011-08-04
JP2006518731A (ja) 2006-08-17
RU2005102110A (ru) 2005-09-20
EP1596868A4 (en) 2006-03-29
PL404315A1 (pl) 2013-08-05
ES2315640T3 (es) 2009-04-01
CY1108583T1 (el) 2014-04-09
CA2493475A1 (en) 2004-09-02
BRPI0405657A (pt) 2005-07-19
MY143740A (en) 2011-07-15
JP4771937B2 (ja) 2011-09-14
CN100577171C (zh) 2010-01-06
EP2000142A1 (en) 2008-12-10
US7749993B2 (en) 2010-07-06
NO20050569L (no) 2005-11-22
TW200418489A (en) 2004-10-01
KR100706727B1 (ko) 2007-04-12
AU2004212842B9 (en) 2009-03-05
DE602004017283D1 (de) 2008-12-04
AR043259A1 (es) 2005-07-20
NO335369B1 (no) 2014-12-01
PL373432A1 (en) 2005-08-22
PT1596868E (pt) 2009-01-14
WO2004073716A1 (en) 2004-09-02
TWI322689B (en) 2010-04-01
RU2008133654A (ru) 2010-02-20
DK1596868T3 (da) 2008-12-08
KR20050105972A (ko) 2005-11-08
HK1084037A1 (zh) 2006-07-21
NO20050569D0 (no) 2005-02-02
AU2009201109A1 (en) 2009-04-09
SI1596868T1 (sl) 2008-12-31
CN1700919A (zh) 2005-11-23
US20050187210A1 (en) 2005-08-25
US20080214523A1 (en) 2008-09-04
RU2346689C2 (ru) 2009-02-20
US7423032B2 (en) 2008-09-09
EP1596868B1 (en) 2008-10-22
EP1596868A1 (en) 2005-11-23
ATE411803T1 (de) 2008-11-15
AU2004212842B2 (en) 2009-01-08
PL218069B1 (pl) 2014-10-31
AU2004212842A1 (en) 2004-09-02

Similar Documents

Publication Publication Date Title
US7749993B2 (en) Method for treating severe heart failure and medicament therefor
EP2059245A1 (en) Bifeprunox doses for treating schizophrenia
JP6328856B2 (ja) 収縮力低下随伴性排尿筋過活動改善剤
HK1084037B (en) Medicament for treating severe heart failure
US20250186405A1 (en) Compound For Use In Treating Narcolepsy
JP3002766B2 (ja) 脳浮腫治療剤
JP3758700B2 (ja) 徐脈性不整脈治療剤
HK40044975A (en) Joint use of compound a and compound b in preparation of medications for treatment of gout or hyperuricemia
JPH0776584A (ja) 内皮細胞障害抑制剤
CN112512526A (zh) 化合物a与化合物b联合在制备治疗痛风或高尿酸血症的药物中的用途
JPH06211657A (ja) 尿酸排泄剤
HK1078012A (en) Therapeutic agent for overactive bladder
HK1133190A (en) Bifeprunox doses for treating schizophrenia
MXPA05011808A (en) Uses of ion channel modulating compounds

Legal Events

Date Code Title Description
FG Grant or registration